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The morbidity and mortality rates of diabetic ne-
phropathy (DN) are increasing. DN, as indicated by
glomerulosclerosis, is a histologic feature of end-
stage renal disease (ESRD) [1]. The degree of protein-
uria is strongly correlated with the progression of
glomerulosclerosis and tubulointerstitial fibrosis [2].
Plasma protein leakage is accelerated across the glo-
merular basement membrane into Bowman’s space.
Downstream of the tubular compartment, proteinuria
induces proinflammatory and profibrogenic injury in
tubular cells, which can facilitate the development of
interstitial fibrosis and tubular atrophy. In addition 
to glomerulosclerosis, the molecular basis of tubu-
lointerstitial fibrosis has yet to be clarified because
the severity of chronic tubulointerstitial injury is
most strongly correlated with impaired renal func-
tion and most accurately predicts renal dysfunction
in patients with ESRD. The most pronounced feature
of chronic kidney disease that progresses to ESRD is
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Tubulointerstitial changes in the diabetic kidney correlate closely with renal fibrosis, and trans-
forming growth factor-beta-1 (TGF-β1) is thought to play a key role in this process. In contrast,
hepatocyte growth factor (HGF) has shown therapeutic effects on injured renal tubules in animal
models. This study was undertaken to test the hypothesis that the preventive effects of HGF may
result from interventions in TGF-β1-mediated signaling and collagen III secretion. We examined
the expression of HGF/HGF receptor (c-Met) and TGF-β1 in renal fibroblasts at multiple time
points. The effects of recombinant human HGF on TGF-β1 expression were studied by RT-PCR
and Western blotting, and the levels of collagen III were measured by ELISA. In the high-glucose
condition, the expression of HGF and c-Met in renal fibroblasts was detected as early as 6 hours
following cell culture while the level of TGF-β1 peaked at 96 hours. The addition of recombinant
human HGF to the culture media dose-dependently inhibited TGF-β1 mRNA expression and
reduced collagen III secretion by 34%. These results indicate that, during hyperglycemia, HGF
inhibits TGF-β1 signaling and type III collagen activation in interstitial fibroblasts. Furthermore, we
should recognize that changes in the balance between HGF and TGF-β1 might be decisive in the
pathogenesis of chronic renal fibrosis. Therefore, administration of HGF to restore this balance
may offer a novel therapeutic intervention in managing renal fibrogenesis in diabetic nephropathy.
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the relentless accumulation of extracellular matrix
(ECM), which leads to widespread glomerular scle-
rosis and interstitial fibrosis [3]. Several lines of evi-
dence [4] have revealed critical roles of transforming
growth factor-beta-1 (TGF-β1) during the progres-
sion of DN: (1) TGF-β1 expression is upregulated by
glucose and promotes ECM accumulation in mesan-
gial cells; (2) TGF-β1 expression levels are markedly
increased in mesangial areas in animals and in patients
after the onset of DN [5]; and (3) neutralization of
TGF-β1 actions with a specific antibody suppresses
kidney hypertrophy and sclerosis in vivo [6]. Thus,
TGF-β1 is now considered to be a key factor that can
aggravate DN.
Hepatocyte growth factor (HGF) was originally
identified as a potent mitogen for mature hepato-
cytes [7], and was later recognized to have the same 
effects on renal tubular cells [8]. In the kidney, HGF
accelerates renal tubular repair after the onset of acute
renal failure, with rapid recovery of tubular morphol-
ogy and function [9]. Administration of exogenous
HGF prevented renal dysfunction and chronic mesan-
gial injuries in a murine model of chronic renal dis-
ease, and had therapeutic effects on ESRD [10]. While
considerable attention has been given to the effects of
HGF in mesangial cells, it remains unclear whether
HGF has similar effects on chronic interstitial injuries.
Therefore, the aim of this study was to investigate the
roles of HGF in fibroblast lesions exposed to high
glucose concentrations. Our data suggest that HGF 
is an effective antifibrogenic factor that can decrease
TGF-β1 production and collagen biosynthesis.
MATERIALS AND METHODS
Materials
Dulbecco’s modified Eagle medium (DMEM) was
purchased from Gibco BRL (Gaithersburg, MD, USA).
Secondary antibodies were from Fuzhou Maixin
Biotechnology Development Co. Ltd. (Fuzhou, Fujian,
China). Glucose and mannitol were purchased from
Sigma-Aldrich Corp. (St Louis, MO, USA). The colla-
gen III enzyme-linked immunosorbent assay (ELISA)
kit was purchased from Shanghai SenYong Science
and Technology Co. (Shanghai, China). The HGF
ELISA kit and goat anti-human c-Met antibody were
purchased from R&D Systems Inc. (Minneapolis,
MN, USA).
Preparation and characterization of human
fibroblast cultures
Primary cultures of kidney fibroblasts were generated
using established methods with some modifications
[11,12]. Briefly, the kidney medulla was dissected from
the cortex, diced, and digested in a collagenase solution
(0.1%) (Shanghai Institute of Pharmaceutical Industry,
China) for 30 minutes at 37°C in a water-bath rocker.
The enzyme reaction was terminated by adding horse
serum. The tissues were centrifuged for 5 minutes 
at 1,000 revolutions/min. After washing twice in
phosphate-buffered saline, the fibroblasts were grown
in serum-free DMEM. Cells were incubated at 37°C
in a humidified atmosphere of 95% air/5% CO2. After
24 hours, the medium was replaced with DMEM
supplemented with 10% fetal bovine serum. Every 2
days, the medium was replaced with fresh medium.
When cells reached confluence, they were passaged
by trypsinization, resuspended, and replated. The
passage number was monitored.
These cells exhibited fibroblast-specific charac-
teristics on immunohistochemical and morphologic
observations (Figure 1). Briefly, the fibroblasts were
positive for vimentin and fibronectin expression, but
negative for the expression of cytokeratin.
In vitro experimental design
The cells were seeded in six-well tissue culture plates.
After reaching confluence, the medium was replaced
with fresh serum-free DMEM for 24 hours because all
of the cells were in quiescent states. In the high-glucose
groups, D-glucose was added to the medium at a
Figure 1. Primary human renal fibroblasts.
concentration of 25 mmol/L. The concentration of
glucose in the control group was 5.5 mmol/L. At the
same time, we used mannitol as an osmolarity con-
trol (5.5 mmol/L glucose + 20 mmol/L mannitol). The
osmolarity was the same as that in the high-glucose
group. The medium was changed every 2 days in
each group. Cells were then collected at 6, 12, 24, 48
and 96 hours from each experimental group to mea-
sure collagen III biosynthesis, and HGF, c-Met and
TGF-β1 mRNA and protein levels. Each experimental
condition was tested in six replicate wells and the
mean was taken to represent an individual experiment.
To examine the effects of HGF on fibroblasts, human
recombinant (rh) HGF (R&D Systems Inc.) was added
to the high-glucose medium at concentrations of 25,
50, 100 or 200 ng/mL. To investigate the role of tran-
scription and protein synthesis of TGF-β1 induced by
HGF, cells were pretreated with or without HGF for
48 hours. To evaluate the ECM of fibroblasts, type III
collagen secretion was measured in the supernatants
of cultured cells. Each experimental condition was
tested in six replicate wells and the mean was taken
to represent an individual experiment.
Effects of glucose concentrations on
expression of HGF, TGF-b1 and 
c-Met mRNA
After the cells had reached confluence under serum
stimulation, RNA was extracted from cells using
RNAzol. The levels of HGF and its receptor c-Met
mRNA were measured by reverse transcription-
polymerase chain reaction (RT-PCR). Glyceraldehyde
3-phosphate dehydrogenase was used as the normal
control. The primers are shown in Table 1 [13].
RNA was quantified by measurement of the ultra-
violet absorbance at 260nm and its purity was assessed
by measuring the optical density ratio at 260 nm and
280 nm. First-strand cDNA was synthesized using 2μg
of total RNA isolated from cells by reverse transcription
with random primers at 37°C for 1.5 hours, in accor-
dance with the manufacturer’s instructions. The cDNA
was then amplified with specific primers designed
for human HGF, c-Met and TGF-β1. The HGF gene
was amplified for 35 cycles of 1 minute at 94°C, 
1 minute at 48°C and 1 minute at 72°C. c-Met was
amplified for 35 cycles of 1 minute at 94°C, 1 minute
at 48°C and 1 minute at 72°C. The TGF-β1 gene was
amplified for 35 cycles of 1 minute at 94°C, 40 sec-
onds at 54°C and 40 seconds at 72°C. The amplifica-
tion products were electrophoresed on 1.5% agarose
gels and stained with ethidium bromide. Quantitation
was carried out by scanning and analyzing the inten-
sity of the band signals using the FR200 instrument
(Shanghai FuRi Institute of Biotechnology, Shanghai
China), installed by Smart View analysis software
(OPTON Co., Germany).
Type III collagen secretion
The level of type III collagen was determined using
an ELISA following the manufacturer’s protocol. At
the end of the procedure, the reaction was stopped
and the optical density of each well was determined
at 492 nm using an automated microplate reader. The
results of the assay were compared as the mean of
duplicate samples against a 10-point standard curve.
Protein HGF secretion
HGF protein levels were determined by an ELISA
(R&D Systems Inc.). The kit utilizes a sandwich meth-
od consisting of three antigen–antibody reaction steps.
Briefly, a monoclonal antibody specific to human HGF
was coated onto 96-well microplates. Fifty-microliters
of standard human HGF or culture supernatant sam-
ples were added to the wells and were incubated for
2 hours at room temperature. After washing three times
with phosphate-buffered saline, 200 μL of an enzyme-
linked polyclonal antibody specific to human HGF
was added and the plates were incubated for another
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Table 1. Primers for hepatocyte growth factor (HGF), c-Met and transforming growth factor-beta-1 (TGF-β1)
Gene Primer Size (bp)
HGF Sense 5’-GAT GTC CAC GGA AGA GGA GA-3’ 301
Antisense 5’-GAG TCA CCT TCC CTC GAT GA-3’
c-Met [13] Sense 5’-TCT TGG GAC ATC AGA GGG TC-3’ 222
Antisense 5’-TGA CTG CAG GAC TGG AAA TG-3’
TGF-β1 Sense 5’-TCT GAA TTC ATG GCC TGG ACA CCA ACT A-3’ 363
Antisense 5’-TCT GTC GAC ACC TCA GCT GCA CTT GCA GGA-3’
2 hours. They were then washed three times before
the enzyme substrate was added. The plates were
allowed to stand for 30 minutes, and the reaction was
stopped by the addition of 50 μL of 1 N H2SO4. The
absorbance was read at 450 nm with a BioTek EL340
automatic microplate reader (BioTek Instruments Inc.,
Winooski, VT, USA).
Protein c-Met and TGF-b1 secretion
The samples were solubilized with lysis buffer at 4°C
for 10 minutes, and the lysates were collected after
centrifugation at 13,000g at 4°C for 10 minutes. The
protein concentration was then determined using
Bradford’s assay. Samples were heated at 100°C for 
3 minutes before loading and separated on a 7% 
SDS-PAGE gel. The proteins were electrotransferred
to a PVDF (polyvinylidene fluoride) membrane. Non-
specific binding to the membrane was blocked with
2% milk and the membrane was incubated overnight
at 4°C with specific anti-human TGF-β1 antibodies or
c-Met antibodies, followed by incubation for 1 hour at
room temperature with the secondary IgG conjugate.
The signals were visualized using the ImageJ system
(National Institutes of Health, Bethesda, MD, USA).
Statistical analysis
All data are expressed as mean ± standard deviation.
Groups were compared using unpaired t tests.
Statistical significance was considered at p < 0.05.
RESULTS
Effects of high glucose on secretion of
collagen III
The secretion of collagen III was increased in response
to the high-glucose medium (25mmol/L glucose) at all
three time points (24, 48 and 96 hours), and peaked at
96 hours with a 3.2-fold increase compared with that
observed in the control groups (5.5 mmol/L glucose),
as shown in Table 2.
Although a similar trend was observed in the man-
nitol group, the difference across the three groups
remained statistically significant. These data suggest
that at least part of the observed increase in collagen
III levels is due to the cellular response to higher osmo-
larity induced by higher concentrations of mannitol
or glucose.
Effects of high glucose concentration on
gene expression of TGF-b1, HGF and c-Met
RT-PCR and a Smart View algorithm were used to
quantify the mRNA levels of TGF-β1, HGF and c-Met
at 6, 12, 24, 48 and 96 hours after exposure to the con-
trol, high glucose or mannitol conditions, as shown
in Figure 2. In the TGF-β1 study, the expression of
TGF-β1 was increased in a time-dependent manner
across the five time periods. No difference among the
three groups in TGF-β1 mRNA was observed at 6 
or 12 hours. However, a > 2-fold increase in TGF-β1
mRNA was recorded at the remaining three time points
and peaked at 96 hours, which was associated with
the greatest difference between the control and high-
glucose groups (43.5 ± 3.42 vs. 103.7 ± 6.21, respec-
tively). Figures 2B and 2C demonstrate the biphasic
mRNA expression profile of HGF and c-Met. A peak
in HGF mRNA expression, which represented almost
a 3-fold increase, was observed as early as 12 hours 
in the high-glucose group. This overexpression then
gradually declined and returned to the baseline level
at 96 hours. Although slightly delayed, a parallel peak
corresponding to a 2.75-fold increase in c-Met gene
expression was found 24 hours after high-glucose
induction.
As discussed above, medium rendered hypotonic
by mannitol or glucose can lead to increases in osmo-
larity. This factor might alter the expression pattern
and partially contribute to the overexpression of these
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Table 2. High glucose (25 mmol/L) enhances type III collagen secretion and suppresses hepatocyte growth factor
(HGF) expression (n = 6)
Time (hr)
5.5mmol/L 25 mmol/L
Mannitol
25 mmol/L glucose +
glucose glucose 50 ng/mL HGF
24 42.69 ± 8.02 98.00 ± 12.33† 70.57 ± 10.19*‡ 96.69 ± 16.33
48 47.47 ± 6.69 120.02 ± 8.20† 77.35 ± 12.51*§ 102.01 ± 5.43‡
96 59.31 ± 4.53 189.31 ± 49.34* 93.44 ± 11.33†‡ 124.36 ± 18.92‡
*p < 0.05 and †p < 0.01 vs. 5.5 mmol/L glucose; ‡p < 0.05 and §p < 0.01 vs. high-glucose group (25 mmol/L).
HGF attenuates injury in renal fibroblasts
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Figure 2. Expression of transforming growth factor-beta-1 (TGF-
b1), hepatocyte growth factor (HGF) and c-Met mRNA. (A)
Time-course of TGF-b1 mRNA expression: TGF-b1 mRNA
expression reached a peak at 96 hours. (B) Time-course of HGF
mRNA expression: HGF mRNA expression reached a peak at 
12 hours. (C) Expression of c-Met mRNA: c-Met mRNA expression
reached a peak at 24 hours. Control group: the concentration of
glucose was 5.5 mmol/L. High-glucose group: the concentration
of glucose was 25 mmol/L. Mannitol group: osmolarity was the
same as the high-glucose group and comprised 5.5 mmol/L glucose
plus 20 mmol/L mannitol. Error bars represent standard deviation. 
The experiments were repeated six times. *p < 0.01 and †p < 0.05,
compared with the control groups at the appropriate times.
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three genes in the mannitol (25 mmol/L) group com-
pared with the normal glucose control group (TGF-β1:
56.5 ± 10.43 vs. 43.5 ± 3.42, p < 0.05; HGF: 41.50 ± 6.61
vs. 28.23 ± 6.59, p < 0.05; c-Met: 63.37 ± 6.01 vs. 29.87 ±
5.05, p < 0.05).
Effects of high glucose on protein expression
of HGF, TGF-b1 and c-Met
We measured the expression level of HGF protein
using a commercially available ELISA kit. As shown
in Table 3, the level of HGF protein reached a peak
only 12 hours after high glucose induction, corre-
sponding to nearly a 20% increase. The HGF protein
level returned to baseline within 96 hours.
We also measured the protein expression level of
TGF-β1 and c-Met using Western blotting. Under the
high glucose condition, TGF-β1 protein increased by
2.1-fold compared with that in the control group at 48
hours (Figures 3A and 3B), an observation similar to
previous studies [13], and this increase continued to
96 hours (Figure 3A). On the other hand, c-Met pro-
tein expression began to increase at 12 hours in the
Table 3. Relative hepatocyte growth factor expression (n = 6)
Time (hr) 5.5 mmol/L glucose 25 mmol/L glucose Mannitol
6 97.67 ± 11.40 157.00 ± 30.81* 66.00 ± 7.00*‡
12 102.73 ± 15.40 177.67 ± 18.15† 40.08 ± 8.88†‡
24 91.33 ± 9.93 105.50 ± 12.76 38.97 ± 8.73†‡
48 94.40 ± 13.56 97.42 ± 11.57 35.00 ± 9.17†‡
96 89.60 ± 13.38 86.60 ± 8.32 25.67 ± 4.04†‡
*p < 0.05 and †p < 0.01 vs. 5.5 mmol/L glucose; ‡p < 0.01 vs. high-glucose group (25 mmol/L).
high-glucose group (Figure 4A), and reached a peak
at 24 hours (Figures 4A and 4B).
Exogenous HGF inhibits TGF-b1 expression
in fibroblasts
To determine the preventive role of HGF on fibrob-
lasts, we examined whether rhHGF affects TGF-β1
mRNA and protein expression.
The addition of various concentrations of rhHGF
into the high-glucose media dose-dependently re-
pressed the glucose-induced increase in TGF-β1, with
a strong correlation coefficient (r = −0.8726, p < 0.01;
Figure 5). This study also revealed that 50 ng/mL of
rhHGF was sufficient to reduce TGF-β1 expression
by 50% (p < 0.05).
Next, we examined the effect of different concen-
trations of rhHGF on the protein levels of TGF-β1
using Western blotting. Consistent with a decrease in
TGF-β1 mRNA, suppressed upregulation of TGF-β1
was found in response to rhHGF administration.
Exogenous HGF modulates collagen III
secretion in fibroblasts
Finally, we investigated the effect of 50 ng/mL rhHGF
on ECM accumulation using type III collagen as the
surrogate marker. An ELISA was used to quantify
collagen III expression in fibroblasts under various
culture conditions, and a significant difference was
observed at 48 and 96 hours (Table 2).
DISCUSSION
Diabetes is the leading cause of ESRD in many devel-
oped countries and DN has emerged as an unseen
epidemic worldwide [1]. Although the mechanisms
accounting for kidney failure in diabetes remain con-
troversial, clinical studies imply that tubulointerstitial
lesions show the strongest correlation with renal fail-
ure in DN [5]. The tubulointerstitium of the diabetic
kidney has become a major research focus. In partic-
ular, in vitro studies [2] have confirmed the original
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Figure 3. (A) Time-course of transforming growth-factor-beta-1
(TGF-b1) protein expression. TGF-b1 expression began to in-
crease after 24 hours in the high-glucose condition, and contin-
ued to increase until 96 hours. Error bars represent standard
deviation. *p < 0.01 and †p < 0.05 compared with the control
group at the appropriate times; ‡p < 0.05 and §p < 0.01 compared
with the high-glucose group at the appropriate times. (B) Bands
corresponding to TGF-b1 in each group after treatment for 
96 hours. The experiments were repeated six times.
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Figure 4. (A) Time-course of c-Met protein expression. Error
bars represent standard deviation. *p<0.05 and †p<0.01 compared
with the control group at the appropriate times; ‡p < 0.05 and
§p < 0.01 compared with the high-glucose group at the appropri-
ate times. (B) Bands corresponding to c-Met in each group after
treatment for 24 hours. The experiments were repeated six times.
observation of cellular interactions within the tubu-
lointerstitial compartment, and that it is an important
site of action for renoprotective therapies in diabetic
kidney disease. We developed a cell culture system
for human kidney fibroblasts in which we could test
the effects of high ambient glucose levels on growth
factor biosynthesis. Fibroblasts constitute the major
cell type in the interstitium, where they interconnect
with tubules, vessels and each other to provide a
scaffold-like structure. The aim of this research was to
study the effects of high glucose on kidney interstitial
fibroblast cells.
Our study shows that the expression of HGF and
its receptor c-Met was increased in fibroblasts in the
early stage of culture in high glucose concentrations.
As a result, we began by investigating the relationship
between HGF/c-Met and high glucose. Although the
molecular mechanism responsible for the stimulation of
HGF/c-Met expression at high glucose concentrations
within fibroblasts is unknown, increased osmolarity
owing to hyperglycemia appears to be one of the
important contributing factors. However, a signifi-
cant difference between the mannitol and glucose
groups, in which osmolarity was comparable, implies
HGF attenuates injury in renal fibroblasts
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Figure 5. Expression of transforming growth-factor-beta-1 (TGF-b1) in human fibroblasts cultured for 48 hours in media containing
hepatocyte growth factor (HGF; 0, 25, 50, 100 or 200 ng/mL). (A) HGF suppressed the expression of TGF-b1 mRNA. (B) HGF 
suppressed the expression of TGF-b1 protein. Error bars represent standard deviation. *p < 0.05 and †p < 0.01 compared with the high-
glucose group at the appropriate times. (C) Bands corresponding to TGF-b1 after treatment with HGF. The experiments were repeated
six times. M = 100-bp ladder marker; GAPDH = glyceraldehyde 3-phosphate dehydrogenase.
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the presence of other mechanisms. One popular hypo-
thesis is the cytokine theory, which proposes that
cytokines and growth factors, including interleukin-1,
interleukin-6, and HGF itself, can upregulate HGF/
c-Met expression in cell culture systems [7,8].
Emerging evidence [13,14] suggests that the HGF/
c-Met axis is an important component of the intercel-
lular signaling pathway that controls the growth and
differentiation of diverse types of cells. HGF not only
promotes tissue repair and regeneration following
acute injury, but also modulates the development and
progression of chronic diseases that are characterized
by progressive tissue fibrosis [15]. Autocrine HGF/
c-Met signaling may also occur in other cell types
within the kidney during development, as exemplified
in embryogenic mesenchymal cells where the c-Met
receptor and HGF are co-expressed [16]. HGF exerts
mitogenic, motogenic and morphogenic effects on
renal epithelial cells to promote epithelial cell regen-
eration and reconstitution of damaged tubules. HGF
also stimulates the gene expression of fibronectin, 
a major component of the ECM, suggesting that it
may modulate matrix remodeling and lead to the
restoration of a normal extracellular environment
[17]. Although the exact mechanisms underlying the
preventive effects of HGF in diabetic renal fibrosis
remain uncertain, some researchers have suggested
that HGF might attenuate fibrosis by suppressing
plasminogen activator inhibitor, an inhibitor of ECM-
degrading enzymes. Consequently, tubulointerstitial
fibrogenic events [14], including overexpression of
TGF-β1, fibroblast hypertrophy and overactive ECM
deposition, were inhibited in diabetic fibroblasts and
appear to mitigate the fibrosis phenotype.
The progression of chronic kidney disease is char-
acterized by the persistent accumulation of ECM, a
predisposition of widespread tissue fibrosis. Previous
studies [13,18] have revealed that high glucose con-
centrations can stimulate the expression of various
matrix components at the mRNA and protein levels.
In diabetic kidneys, the synthesis of collagen III, colla-
gen IV, fibronectin, and laminin is increased, of which
collagen IV overexpression can be abolished by HGF
in cultured human mesangial cells [19]. To determine
the effects of HGF on matrix protein overproduction,
we added various concentrations of rhHGF to cultured
renal fibroblasts exposed to hyperglycemic conditions
and found decreased expression of collagen III, indi-
cating that HGF may prevent fibrosis by suppressing
ECM expression. It is known that the expression of
HGF/c-Met in a high-glucose concentration environ-
ment is time-dependent. The activation of HGF/c-Met
expression usually takes place within 12–24 hours of
exposure to high glucose. After this period, a timing
preceding and paralleling significant renal hypertro-
phy is found [14]. After 24 hours, the expression of
HGF/c-Met is suppressed while the expression of
TGF-β1 is increased. This profile is known to stimulate
renal interstitial fibroblasts and glomerular mesan-
gial cells to undergo myofibroblastic activation [20],
as characterized by the induction of α-smooth muscle
actin expression and overproduction of ECM compo-
nents. TGF-β1 also induces the tubular epithelial–
mesenchymal transition [19], a phenotypic conversion
that plays a critical role in generating matrix-producing
effector cells. In addition, TGF-β1 is able to induce
kidney cells to undergo apoptosis [21], leading to cap-
illary loss, and tubular atrophy. Such broad actions of
TGF-β1 will eventually lead to tissue fibrosis [22]. In
our study, high glucose induced the expression of
steady-state mRNA and protein levels of TGF-β1 after
48 hours in the high-glucose condition.
Finally, it is important to discuss the cause-and-
effect relationship between the reciprocal expression
pattern of HGF and TGF-β1 in vitro. HGF-mediated
inhibition of TGF-β1 expression has been consistently
reported in many studies utilizing various models of
chronic kidney disease, which may provide an expla-
nation for its therapeutic efficacy [16,23,24]. Recent
studies using human mesangial cells have also demon-
strated that HGF can suppress TGF-β1 expression
induced by a high concentration of glucose [14]. HGF
also represses TGF-β1 production [25,26]. Thus, in
our study, it seems that HGF alters TGF-β1 regulation
at multiple levels. HGF suppressed the expression of
TGF-β1 after 48 hours. Furthermore, HGF decreased
TGF-β1 mRNA in a dose-dependent fashion, and HGF
abolished TGF-β1 protein expression. Therefore, we
believe that during the rapid progression to high glu-
cose, the earlier increase in expression of HGF/c-Met
in fibroblasts is a beneficial effect.
In vitro studies have revealed that HGF specifi-
cally counteracts many profibrotic actions of TGF-β1,
suggesting that the balance between HGF and TGF-β1
may play a decisive role in the pathogenesis of chronic
renal fibrosis [27]. Broadly, HGF and TGF-β1 function
as the Yin and Yang of tissue fibrotic signals and elicit
opposite effects [23]. Therefore, disturbance of the
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balance between HGF and TGF-β1 activities will even-
tually cause disastrous consequences.
If the injurious stimulus is transient, such as that
after an acute insult, HGF signaling will dominate and
prevail, resulting in tissue repair and regeneration,
perhaps leading to complete recovery. On the other
hand, if the injury is chronic in nature, such as pro-
longed exposure to high glucose, a potential mecha-
nism for regulating the balance may involve TGF-β1
expression, which progressively increases throughout
the course of the injury, whereas HGF levels initially
increase but gradually decline, possibly due to inhi-
bition by TGF-β1. Thus, the net effect after chronic
injury is to shift the balance between TGF-β1 and
HGF, to favor the profibrotic TGF-β1. Accordingly, the
duration of injury seems to determine the ratio of TGF-
β1 and HGF, and thereby the ultimate outcome of the
tissue responses. Taken together, we hypothesize that
there may be reciprocal mechanisms, based on TGF-
β1 and HGF expression, that regulate the progression
of glomerular and tubulointerstitial fibrosis in chronic
renal diseases and that administration of HGF may
offer a novel molecular pathogenesis-based strategy
to limit renal fibrosis. Alternatively, novel specific
approaches that enhance or sustain endogenous HGF
production could be developed to limit TGF-β1 over-
expression and protect against chronic renal failure.
In summary, HGF exerts its antifibrotic actions by
precisely targeting cellular processes that are essen-
tial for renal fibrogenesis. The balance between TGF-β1
and HGF seems to play a critical role in determining
whether the injured tissues undergo recovery or
fibrogenesis.
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肝細胞生長因子抑制人腎間質成纖維細胞膠原合成
和轉化生長因子 —β1 表達
牟姍  王琴  施蓓莉  顧樂怡  倪兆慧
上海交通大學醫學院附屬仁濟醫院腎臟科
糖尿病腎病過程中，當腎小球濾過率下降，常常伴有腎小管間質病變。此項研究中，
採用人腎臟成纖維細胞培養系統，探討肝細胞生長因子 (HGF) 對高糖誘導的腎間質
成纖維細胞損傷產生的作用。用消化法體外培養人腎間質成纖維細胞，用 D-葡萄糖
刺激細胞，造成高糖環境。另外高糖環境下外源加入 rHGF 誘導細胞。以酶聯免疫吸
附法檢測 III 型膠原情況，用 RT-PCR 檢測細胞 HGF 和 TGF-β1 基因表達，
Western blot 方法檢測 TGF-β1 蛋白合成。高糖預處理過的細胞 III 型膠原合成增
加。同時觀察到高糖作用早期 HGF 表達升高，隨著作用時間延長，其表達量下降，
而 TGF-β1 出現持續高表達。同時外源加入 HGF 可以抑制 TGF-β1 基因和蛋白表
達，對 III 型膠原合成產生抑制作用。體外高糖環境促進 III 型膠原合成和 TGF-β1 
持續高表達。rHGF 可以部分抑制 III 型膠原和 TGF-β1 表達，從而發揮延緩間質損
傷的作用。局部的 HGF/c-met 系統在糖尿病腎病過程中起重要作用。
關鍵詞：肝細胞生長因子受體，糖尿病腎病，肝細胞生長因子，間質纖維化，轉化生長因子 —β1
(高雄醫誌 2009;25:577–87)
